TerminatedPhase 2NCT03924154
A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Altavant Sciences GmbH
- Principal Investigator
- Ed Parsley, DOAltavant Sciences
- Intervention
- RVT-1201(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2019 – 2020
Study locations (23)
- Pulmonary Associates, PA, Phoenix, Arizona, United States
- University of California Davis Medical Center, Sacramento, California, United States
- SBPA Research LLC, Santa Barbara, California, United States
- University of Colorado, Aurora, Colorado, United States
- George Washington Medical Faculty Associates - Pulmonary Hypertension Program, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States
- Central Florida Pulmonary Group, P.A., Orlando, Florida, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States
- Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Baystate Medical Center, Springfield, Massachusetts, United States
- Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- +8 more locations on ClinicalTrials.gov
Collaborators
Altavant Sciences, Inc. · PPD Development, LP
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03924154 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →